Investing
Europe’s STOXX 600 falls as tech, healthcare shares drag
Published by Jessica Weisman-Pitts
Posted on November 15, 2024
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Jessica Weisman-Pitts
Posted on November 15, 2024
By Shashwat Chauhan
(Reuters) -Europe’s STOXX 600 fell on Friday, dragged by technology and healthcare stocks, keeping the index on track for its fourth successive weekly drop.
The pan-European STOXX 600 benchmark index slipped 0.5%, hovering near a three-month low hit earlier this week.
The technology sub-index dropped 1.7%, with chipmaker ASML among top decliners, after U.S. firm Applied Materials forecast first-quarter revenue below estimates, a sign of sluggish demand for the chipmaking equipment outside of AI-powered chips.
Healthcare stocks shed 2.1%, with Bavarian Nordic sliding 17% after the Danish biotech firm posted a lower-than-expected core profit for the third quarter, 2025 orders below expectations.
European vaccine makers came under pressure after U.S. President-elect Donald Trump said he has selected Robert F. Kennedy Jr., an environmental activist who has spread misinformation on vaccines, to lead the Department of Health and Human Services.
Sanofi fell 2.9%, while GSK lost 2.2%.
The Swiss benchmark, which houses the bulk of European healthcare firms, declined 0.8%.
European equities were rocked this week as investors fretted over U.S.-China relations after Trump was expected to tap a China hawk to be his secretary of state, while some downbeat earnings throughout this week also compounded losses.
A lower close on Wall Street overnight also weighed on sentiment, after Federal Reserve Chair Jerome Powell said the U.S. central bank does not need to rush to lower interest rates.
The post-election rally paused for breath, with the latest Fed comments on the economy stopping the surge in its tracks,” said Richard Hunter, head of markets at online investment platform interactive investor.
Elsewhere, Britain’s economy contracted unexpectedly in September and growth slowed to a crawl over the third quarter.
Consumer prices in France rose 1.6% year on year in October, revising slightly up its preliminary reading of 1.5%, while Italian EU-harmonised consumer prices (HICP) rose 0.3% month on month in October and were up 1.0% from a year earlier.
Among individual stocks, Evotec jumped close to 20% after Halozyme Therapeutics said it has proposed to buy the German drug developer for about 2 billion euros ($2.11 billion).
Generali advanced 5.5%, after Italy’s top insurer beat estimates for nine-month profits despite a 930 million euro hit from natural disasters.
($1 = 0.9471 euros)
(Reporting by Shashwat Chauhan in Bengaluru; Editing by Rashmi Aich)